
List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/3618351/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Disentangling Independent and Mediated Causal Relationships Between Blood Metabolites, Cognitive Factors, and Alzheimer's Disease. Biological Psychiatry Global Open Science, 2022, 2, 167-179.	2.2	6
2	Metabolic correlates of late midlife cognitive outcomes: findings from the 1946 British Birth Cohort. Brain Communications, 2022, 4, fcab291.	3.3	9
3	Circulating Metabolome and White Matter Hyperintensities in Women and Men. Circulation, 2022, 145, 1040-1052.	1.6	17
4	Association between polygenic risk score of Alzheimer's disease and plasma phosphorylated tau in individuals from the Alzheimer's Disease Neuroimaging Initiative. Alzheimer's Research and Therapy, 2021, 13, 17.	6.2	35
5	Mendelian randomization identifies blood metabolites previously linked to midlife cognition as causal candidates in Alzheimer's disease. Proceedings of the National Academy of Sciences of the United States of America, 2021, 118, .	7.1	35
6	Disentangling the Complex Relationship Between Hypertension and Dementia. Biological Psychiatry, 2021, 89, 742-744.	1.3	1
7	Assessing Genetic Overlap and Causality Between Blood Plasma Proteins and Alzheimer's Disease. Journal of Alzheimer's Disease, 2021, 83, 1825-1839.	2.6	5
8	A genome-wide association study with 1,126,563 individuals identifies new risk loci for Alzheimer's disease. Nature Genetics, 2021, 53, 1276-1282.	21.4	430
9	A genome-wide association study of plasma phosphorylated tau181. Neurobiology of Aging, 2021, 106, 304.e1-304.e3.	3.1	5
10	Sex-Specific Metabolic Pathways Were Associated with Alzheimer's Disease (AD) Endophenotypes in the European Medical Information Framework for AD Multimodal Biomarker Discovery Cohort. Biomedicines, 2021, 9, 1610.	3.2	7
11	Hypertension, brain training and cognition in the healthy adults aged over 50 years: An online longitudinal study. Alzheimer's and Dementia, 2021, 17, .	0.8	0
12	Psychosis-associated DNA methylomic variation in Alzheimer's disease cortex. Neurobiology of Aging, 2020, 89, 83-88.	3.1	13
13	An epigenome-wide association study of Alzheimer's disease blood highlights robust DNA hypermethylation in the HOXB6 gene. Neurobiology of Aging, 2020, 95, 26-45.	3.1	51
14	Genome-wide Meta-analysis Finds the ACSL5-ZDHHC6 Locus Is Associated with ALS and Links Weight Loss to the Disease Genetics. Cell Reports, 2020, 33, 108323.	6.4	41
15	Integrated lipidomics and proteomics network analysis highlights lipid and immunity pathways associated with Alzheimer's disease. Translational Neurodegeneration, 2020, 9, 36.	8.0	37
16	Association of TREM2 variants and sphingolipid levels with AD in blood and brain. Alzheimer's and Dementia, 2020, 16, e046579.	0.8	0
17	Urinary metabolic phenotyping for Alzheimer's disease. Scientific Reports, 2020, 10, 21745.	3.3	30
18	Alzheimer's disease-related dysregulation of mRNA translation causes key pathological features with ageing. Translational Psychiatry, 2020, 10, 192.	4.8	37

#	Article	IF	CITATIONS
19	Lifestyle mediates the role of nutrient-sensing pathways in cognitive aging: cellular and epidemiological evidence. Communications Biology, 2020, 3, 157.	4.4	27
20	Exploration of Plasma Lipids in Mild Cognitive Impairment due to Alzheimer's Disease. Journal of Alzheimer's Disease, 2020, 77, 1117-1127.	2.6	5
21	Examining the association between genetic liability for schizophrenia and psychotic symptoms in Alzheimer's disease. Translational Psychiatry, 2019, 9, 273.	4.8	36
22	Primary fatty amides in plasma associated with brain amyloid burden, hippocampal volume, and memory in the European Medical Information Framework for Alzheimer's Disease biomarker discovery cohort. Alzheimer's and Dementia, 2019, 15, 817-827.	0.8	62
23	A metaboliteâ€based machine learning approach to diagnose Alzheimerâ€type dementia in blood: Results from the European Medical Information Framework for Alzheimer disease biomarker discovery cohort. Alzheimer's and Dementia: Translational Research and Clinical Interventions, 2019, 5, 933-938.	3.7	70
24	Genome-wide meta-analysis identifies new loci and functional pathways influencing Alzheimer's disease risk. Nature Genetics, 2019, 51, 404-413.	21.4	1,625
25	Lifetime cognition and late midlife blood metabolites: findings from a British birth cohort. Translational Psychiatry, 2018, 8, 203.	4.8	21
26	Association between Plasma Ceramides and Phosphatidylcholines and Hippocampal Brain Volume in Late Onset Alzheimer's Disease. Journal of Alzheimer's Disease, 2017, 60, 809-817.	2.6	72
27	No Genetic Overlap Between Circulating Iron Levels and Alzheimer's Disease. Journal of Alzheimer's Disease, 2017, 59, 85-99.	2.6	10
28	Rheumatoid arthritis and risk for Alzheimer's disease: a systematic review and meta-analysis and a Mendelian Randomization study. Scientific Reports, 2017, 7, 12861.	3.3	27
29	Genome-wide meta-analysis associates HLA-DQA1/DRB1 and LPA and lifestyle factors with human longevity. Nature Communications, 2017, 8, 910.	12.8	118
30	Association of blood lipids with Alzheimer's disease: AÂcomprehensiveÂlipidomics analysis. Alzheimer's and Dementia, 2017, 13, 140-151.	0.8	144
31	[F1–02–02]: DISCOVERY AND VALIDATION OF MULTIMODAL BIOMARKER SIGNATURES RELATING TO ALZHEIMER'S DISEASE PATHOLOGY AND PROGRESSION. Alzheimer's and Dementia, 2017, 13, P174.	0.8	0
32	Longitudinal Protein Changes in Blood Plasma Associated with the Rate of Cognitive Decline in Alzheimer's Disease. Journal of Alzheimer's Disease, 2016, 49, 1105-1114.	2.6	30
33	Association of a Locus in the <i>CAMTA1</i> Gene With Survival in Patients With Sporadic Amyotrophic Lateral Sclerosis. JAMA Neurology, 2016, 73, 812.	9.0	57
34	The effect of increased genetic risk for Alzheimer's disease on hippocampal and amygdala volume. Neurobiology of Aging, 2016, 40, 68-77.	3.1	115
35	Pattern of Smell Identification Impairment in Alzheimer's Disease. Journal of Alzheimer's Disease, 2015, 46, 381-387.	2.6	33
36	Lipidomics comparing DCD and DBD liver allografts uncovers lysophospholipids elevated in recipients undergoing early allograft dysfunction. Scientific Reports, 2015, 5, 17737.	3.3	22

#	Article	IF	CITATIONS
37	No Evidence to Suggest that the Use of Acetylcholinesterase Inhibitors Confounds the Results of Two Blood-Based Biomarker Studies in Alzheimer's Disease. Journal of Alzheimer's Disease, 2015, 47, 741-750.	2.6	2
38	O4-05-05: Genetic influences on metabolite levels in Alzheimer's disease. , 2015, 11, P279-P280.		0
39	Associations between Potentially Modifiable Risk Factors and Alzheimer Disease: A Mendelian Randomization Study. PLoS Medicine, 2015, 12, e1001841.	8.4	153
40	Genetic Predisposition to Increased Blood Cholesterol and Triglyceride Lipid Levels and Risk of Alzheimer Disease: A Mendelian Randomization Analysis. PLoS Medicine, 2014, 11, e1001713.	8.4	75
41	Evidence of altered phosphatidylcholine metabolism in Alzheimer's disease. Neurobiology of Aging, 2014, 35, 271-278.	3.1	256
42	Alleles that increase risk for type 2 diabetes mellitus are not associated with increased risk for Alzheimer's disease. Neurobiology of Aging, 2014, 35, 2883.e3-2883.e10.	3.1	9
43	Cross-region reduction in 5-hydroxymethylcytosine in Alzheimer's disease brain. Neurobiology of Aging, 2014, 35, 1850-1854.	3.1	114
44	Alzheimer's disease biomarker discovery using SOMAscan multiplexed protein technology. Alzheimer's and Dementia, 2014, 10, 724-734.	0.8	182
45	Alzheimer's disease susceptibility variants in the MS4A6A gene are associated with altered levels of MS4A6A expression in blood. Neurobiology of Aging, 2014, 35, 279-290.	3.1	56
46	Smell identification function as a severity and progression marker in Alzheimer's disease. International Psychogeriatrics, 2013, 25, 1157-1166.	1.0	68
47	Meta-analysis of 74,046 individuals identifies 11 new susceptibility loci for Alzheimer's disease. Nature Genetics, 2013, 45, 1452-1458.	21.4	3,741
48	Candidate Blood Proteome Markers of Alzheimer's Disease Onset and Progression: A Systematic Review and Replication Study. Journal of Alzheimer's Disease, 2013, 38, 515-531.	2.6	160
49	The deletion variant of α2b-adrenergic receptor is associated with decreased risk in Alzheimer's disease and mild cognitive impairment. Journal of the Neurological Sciences, 2013, 328, 19-23.	0.6	12
50	HLA-DP and IL28B Polymorphisms: Influence of Host Genome on Hepatitis B Surface Antigen Seroclearance in Chronic Hepatitis B. Clinical Infectious Diseases, 2013, 56, 1695-1703.	5.8	58
51	A Blood Gene Expression Marker of Early Alzheimer's Disease. Journal of Alzheimer's Disease, 2013, 33, 737-753.	2.6	91
52	Inflammatory Proteins in Plasma Are Associated with Severity of Alzheimer's Disease. PLoS ONE, 2013, 8, e64971.	2.5	122
53	Mitochondrial Dysfunction and Immune Activation are Detectable in Early Alzheimer's Disease Blood. Journal of Alzheimer's Disease, 2012, 30, 685-710.	2.6	141
54	Alzheimer's disease and age-related macular degeneration have different genetic models for complement gene variation. Neurobiology of Aging, 2012, 33, 1843.e9-1843.e17.	3.1	24

#	Article	IF	CITATIONS
55	Association of serotonin and dopamine gene pathways with behavioral subphenotypes in dementia. Neurobiology of Aging, 2012, 33, 791-803.	3.1	49
56	Genetic variants influencing human aging from late-onset Alzheimer's disease (LOAD) genome-wide association studies (GWAS). Neurobiology of Aging, 2012, 33, 1849.e5-1849.e18.	3.1	43
57	Complement activation as a biomarker for Alzheimer's disease. Immunobiology, 2012, 217, 204-215.	1.9	59
58	Missense substitutions associated with behavioural disturbances in Alzheimer's disease (AD). Brain Research Bulletin, 2012, 88, 394-405.	3.0	6
59	Combinatorial Markers of Mild Cognitive Impairment Conversion to Alzheimer's Disease - Cytokines and MRI Measures Together Predict Disease Progression. Journal of Alzheimer's Disease, 2011, 26, 395-405.	2.6	47
60	Common variants at ABCA7, MS4A6A/MS4A4E, EPHA1, CD33 and CD2AP are associated with Alzheimer's disease. Nature Genetics, 2011, 43, 429-435.	21.4	1,708
61	No evidence that extended tracts of homozygosity are associated with Alzheimer's disease. American Journal of Medical Genetics Part B: Neuropsychiatric Genetics, 2011, 156, 764-771.	1.7	17
62	Deep Sequencing of the Nicastrin Gene in Pooled DNA, the Identification of Genetic Variants That Affect Risk of Alzheimer's Disease. PLoS ONE, 2011, 6, e17298.	2.5	21
63	Effect of APOE ε4 Allele on Cortical Thicknesses and Volumes: The AddNeuroMed Study. Journal of Alzheimer's Disease, 2010, 21, 947-966.	2.6	82
64	Genetic Evidence Implicates the Immune System and Cholesterol Metabolism in the Aetiology of Alzheimer's Disease. PLoS ONE, 2010, 5, e13950.	2.5	347
65	Risk of developing dementia in people with diabetes and mild cognitive impairment. British Journal of Psychiatry, 2010, 196, 36-40.	2.8	115
66	Association of Plasma Clusterin Concentration With Severity, Pathology, and Progression in Alzheimer Disease. Archives of General Psychiatry, 2010, 67, 739.	12.3	353
67	Genes of the serotonergic and dopaminergic pathways and their interaction affect the expression of Behavioural and Psychological Symptoms in Dementia (BPSD) Nature Precedings, 2009, , .	0.1	0
68	Variants of the elongator protein 3 (ELP3) gene are associated with motor neuron degeneration. Human Molecular Genetics, 2009, 18, 472-481.	2.9	512
69	Genome-wide association study identifies variants at CLU and PICALM associated with Alzheimer's disease. Nature Genetics, 2009, 41, 1088-1093.	21.4	2,697
70	Positional Pathway Screen of wnt Signaling Genes in Schizophrenia: Association with DKK4. Biological Psychiatry, 2008, 63, 13-16.	1.3	37